Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO

Pierre‐Yves Dumas, Emmanuel Raffoux, Emilie Bérard, Sarah Bertoli, Maël Heiblig, Yohann Desbrosses, Caroline Bonmati, Cécile Pautas, Juliette Lambert, Corentin Orvain, Anne Banos, Florence Pasquier, Pierre Péterlin, Tony Marchand, Madalina Uzunov, Jamilé Frayfer, Pascal Turlure, Thomas Cluzeau, Éric Jourdan, Chantal Himberlin, Emmanuelle Tavernier, Alban Villate, Stéphanie Haïat, Marie‐Lorraine Chrétien, Martin Carré, Sylvain Chantepie, Ioana Vaida, Mathieu Wémeau, Safia Chebrek, Gaëlle Guillerm, Romain Guièze, Houria Debarri, Eve Gehlkopf, Kamel Laribi, Ambroise Marçais, Alberto Santagostino, Marie C. Béné, Ariane Mineur, Arnaud Pigneux, Hervé Dombret, Christian Récher